Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 13Gastrointestinal 10Genitourinary 8Gynecologic 5Other solid neoplasm 3CNS 3Sarcoma 2Lymphoid 2Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neoplastic Syndromes, Hereditary 1Kidney Neoplasms 1Bone Neoplasms 1

Interventions

lutetium Lu 177 dotatate 30Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7X-Rays 6Etoposide 6Capecitabine 6surufatinib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Testing × Endocrine × 1 year × Clear all
NCT03160274 2025-10-15

Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

The University of Texas Health Science Center at San Antonio

Recruiting
2,000 enrolled
CNSEndocrineGenitourinaryHead & NeckSarcoma

Bone Neoplasms, Kidney Neoplasms, Neoplastic Syndromes, Hereditary, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡